Carisma Therapeutics, Inc. (CARM)

Carisma Therapeutics Stock Forecast

Stock Price Forecast

The 3 analysts that cover Carisma Therapeutics stock have a consensus rating of "Hold" and an average price target of $0.90, which forecasts a 281.36% increase in the stock price over the next year. The lowest target is $0.70 and the highest is $1.00.

Price Target: $0.90 (+281.36%)

Analyst Consensus: Hold

Target	Low	Average	Median	High
Price	$0.70	$0.90	$1.00	$1.00
Change	+196.61%	+281.36%	+323.73%	+323.73%

Analyst Ratings

The average analyst rating for Carisma Therapeutics stock is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.

Recommendation Trends

Rating	Mar '25	Apr '25	May '25	Jun '25	Jul '25	Aug '25
Strong Buy	1	1	1	1	1	1
Buy	0	0	0	0	0	0
Hold	4	4	4	4	4	4
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	5	5	5	5	5	5

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Jason Kolbert D. Boral Capital	D. Boral Capital	Strong Buy Maintains $1	Strong Buy	Maintains	$1	+323.73%	Aug 8, 2025
Jason Kolbert D. Boral Capital	D. Boral Capital	Strong Buy Maintains $12 → $1	Strong Buy	Maintains	$12 → $1	+323.73%	Apr 1, 2025
Jason Kolbert D. Boral Capital	D. Boral Capital	Strong Buy Maintains $12	Strong Buy	Maintains	$12	+4,984.75%	Jan 17, 2025
Jason Kolbert D. Boral Capital	D. Boral Capital	Strong Buy Maintains $12	Strong Buy	Maintains	$12	+4,984.75%	Jan 13, 2025
Mitchell Kapoor HC Wainwright & Co.	HC Wainwright & Co.	Strong Buy → Hold Downgrades n/a	Strong Buy → Hold	Downgrades	n/a	n/a	Dec 16, 2024

More Analyst Ratings

Financial Forecast

Revenue This Year

17.85M

Decreased by -9.08%

from 19.63M

Revenue Next Year

n/a

from 17.85M

EPS This Year

-0.66

from -1.46

EPS Next Year

-0.67

from -0.66

Fiscal Year	FY 2020	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026	FY 2027
Period Ending	Dec 31, 2020	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026	Dec 31, 2027
Revenue	-	-	9.83M	14.92M	19.63M	17.85M	-	-
Revenue Growth	-	-	-	51.71%	31.59%	-9.08%	-	-
EPS	-26.66	-37.62	-28.77	-2.59	-1.46	-0.66	-0.67	-0.56
EPS Growth	-	-	-	-	-	-	-	-
Forward PE	-	-	-	-	-	-	-	-
No. Analysts	-	-	-	-	-	4	3	3

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2025	2026	2027	2028	2029
High	21.0M	n/a	n/a
Avg	17.9M	n/a	n/a
Low	14.7M	n/a	n/a

Revenue Growth

Revenue Growth	2025	2026	2027	2028	2029
High	7.0%	-	-
Avg	-9.1%	-	-
Low	-25.1%	-	-

EPS Forecast

EPS	2025	2026	2027	2028	2029
High	-0.43	-0.69	-0.58
Avg	-0.66	-0.67	-0.56
Low	-0.86	-0.65	-0.54

EPS Growth

EPS Growth	2025	2026	2027	2028	2029
High	-	-	-
Avg	-	-	-
Low	-	-	-

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.